This case study examines the strategic business issue surrounding the failed joint venture between Pfizer and Hisun, focusing on the factors that led to its termination. The venture, aimed at tapping into the growing Chinese market for branded generic medicines, was plagued by data integrity issues at Hisun's pharmaceutical plant, including data mismanagement and attempts to conceal test failures. Pfizer's lack of strategies to address these weaknesses and the resulting damage to its reputation ultimately led to its exit from the joint venture. The analysis includes a PESTLE analysis of the Chinese market, an evaluation of strategic decisions, and recommendations for Pfizer to improve its practices in future strategic alliances. The study emphasizes the importance of due diligence, ethical conduct, and robust risk management in international partnerships.
![[object Object]](/_next/static/media/star-bottom.7253800d.svg)
